Cargando…
Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649564/ https://www.ncbi.nlm.nih.gov/pubmed/36387802 http://dx.doi.org/10.12998/wjcc.v10.i31.11617 |
_version_ | 1784827823895085056 |
---|---|
author | Zeng, Shu-Ying Yuan, Jin Lv, Min |
author_facet | Zeng, Shu-Ying Yuan, Jin Lv, Min |
author_sort | Zeng, Shu-Ying |
collection | PubMed |
description | BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal. CONCLUSION: Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC. |
format | Online Article Text |
id | pubmed-9649564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-96495642022-11-15 Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report Zeng, Shu-Ying Yuan, Jin Lv, Min World J Clin Cases Case Report BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal. CONCLUSION: Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC. Baishideng Publishing Group Inc 2022-11-06 2022-11-06 /pmc/articles/PMC9649564/ /pubmed/36387802 http://dx.doi.org/10.12998/wjcc.v10.i31.11617 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Zeng, Shu-Ying Yuan, Jin Lv, Min Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report |
title | Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report |
title_full | Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report |
title_fullStr | Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report |
title_full_unstemmed | Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report |
title_short | Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report |
title_sort | favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649564/ https://www.ncbi.nlm.nih.gov/pubmed/36387802 http://dx.doi.org/10.12998/wjcc.v10.i31.11617 |
work_keys_str_mv | AT zengshuying favorableresponseofprimarypulmonarylymphoepitheliomalikecarcinomatosintilimabcombinedwithchemotherapyacasereport AT yuanjin favorableresponseofprimarypulmonarylymphoepitheliomalikecarcinomatosintilimabcombinedwithchemotherapyacasereport AT lvmin favorableresponseofprimarypulmonarylymphoepitheliomalikecarcinomatosintilimabcombinedwithchemotherapyacasereport |